Commodore Capital LP Takes Position in SAB Biotherapeutics, Inc. $SABS

Key Points

• Commodore Capital LP purchased 4,401,500 shares of SAB Biotherapeutics (≈$8.85M) and owned about 42.28% of the company according to its latest SEC filing.
• Analysts maintain a Moderate Buy consensus with an average price target of $10.00 (range $7–$15), and the company recently missed quarterly EPS (reported ($0.46) vs. ($0.16) estimate) with forecasts of -3.69 EPS for the year.
• SABS trades near $4.15 with a market cap of $211.44 million, a 52-week range of $1.00–$6.60, and reported high liquidity ratios (quick ratio 10.50, current ratio 9.46).

Commodore Capital LP purchased a new position in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 4,401,500 shares of the company's stock, valued at approximately $8,847,000. Commodore Capital LP owned about 42.28% of SAB Biotherapeutics as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in SABS. ADAR1 Capital Management LLC purchased a new position in SAB Biotherapeutics during the 3rd quarter valued at about $30,000. Dimensional Fund Advisors LP purchased a new stake in shares of SAB Biotherapeutics in the third quarter valued at about $32,000. Virtu Financial LLC acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $40,000. Finally, HB Wealth Management LLC acquired a new stake in shares of SAB Biotherapeutics in the third quarter valued at approximately $618,000. 7.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. Chardan Capital lifted their price objective on SAB Biotherapeutics from $12.00 to $14.00 and gave the stock a "buy" rating in a research report on Wednesday. HC Wainwright dropped their price target on SAB Biotherapeutics from $9.00 to $7.00 and set a "buy" rating for the company in a research report on Tuesday, March 10th. UBS Group started coverage on SAB Biotherapeutics in a report on Wednesday, January 7th. They issued a "buy" rating and a $7.00 price target for the company. Guggenheim started coverage on SAB Biotherapeutics in a research report on Friday, December 19th. They issued a "buy" rating and a $15.00 price objective on the stock. Finally, Zacks Research lowered SAB Biotherapeutics from a "hold" rating to a "strong sell" rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $10.00.

SAB Biotherapeutics Price Performance

Shares of NASDAQ:SABS opened at $4.15 on Friday. The company has a market cap of $211.44 million, a P/E ratio of -1.79 and a beta of 0.59. The business has a fifty day simple moving average of $4.02 and a 200-day simple moving average of $3.37. SAB Biotherapeutics, Inc. has a 52 week low of $1.00 and a 52 week high of $6.60. The company has a quick ratio of 10.50, a current ratio of 9.46 and a debt-to-equity ratio of 0.02.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last released its earnings results on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.30). Equities research analysts forecast that SAB Biotherapeutics, Inc. will post -3.69 EPS for the current year.

SAB Biotherapeutics Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

Want to see what other hedge funds are holding SABS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAB Biotherapeutics, Inc. (NASDAQ:SABS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.